Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Yokell MA, Zaller ND, Green TC, Rich JD.

Curr Drug Abuse Rev. 2011 Mar;4(1):28-41. Review.

2.

From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

Ling W, Jacobs P, Hillhouse M, Hasson A, Thomas C, Freese T, Sparenborg S, McCarty D, Weiss R, Saxon A, Cohen A, Straus M, Brigham G, Liu D, McLaughlin P, Tai B.

J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S53-60. doi: 10.1016/j.jsat.2010.01.009.

3.

The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.

Mammen K, Bell J.

Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Review.

PMID:
19708849
4.

Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.

Balhara YP.

J Opioid Manag. 2013 Jul-Aug;9(4):237. No abstract available.

PMID:
24380101
5.

Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?

Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, Sylvestre DL.

J Addict Med. 2012 Sep;6(3):179-85. doi: 10.1097/ADM.0b013e318257377f.

6.

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.

Am J Addict. 2004;13 Suppl 1:S42-66.

7.

Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.

Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.

Clin Drug Investig. 2010;30 Suppl 1:27-31. doi: 10.2165/11536030-000000000-00000.

PMID:
20450243
8.

Buprenorphine and naloxone for heroin dependence.

Johnson RE, McCagh JC.

Curr Psychiatry Rep. 2000 Dec;2(6):519-26. Review.

PMID:
11123005
9.

Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.

Larance B, Degenhardt L, Lintzeris N, Bell J, Winstock A, Dietze P, Mattick R, Ali R, Horyniak D.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):265-73. doi: 10.1016/j.drugalcdep.2011.04.002.

PMID:
21565452
10.

Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.

Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND.

J Addict Med. 2011 Sep;5(3):175-80. doi: 10.1097/ADM.0b013e3182034e31.

11.
12.

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.

Strain EC, Stoller K, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

PMID:
10928310
13.

The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.

Horyniak D, Dietze P, Larance B, Winstock A, Degenhardt L.

Int J Drug Policy. 2011 Mar;22(2):167-71. doi: 10.1016/j.drugpo.2010.10.004.

PMID:
21112758
14.

Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.

Yokell MA, Zaller ND, Green TC, McKenzie M, Rich JD.

J Opioid Manag. 2012 Jan-Feb;8(1):63-6.

15.

Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care.

Apelt SM, Scherbaum N, Gölz J, Backmund M, Soyka M.

Pharmacopsychiatry. 2013 May;46(3):94-107. doi: 10.1055/s-0032-1330033.

PMID:
23293011
16.

Opioid dependence treatment, including buprenorphine/naloxone.

Raisch DW, Fye CL, Boardman KD, Sather MR.

Ann Pharmacother. 2002 Feb;36(2):312-21. Review.

PMID:
11847954
17.

Diffusion and diversion of suboxone: an exploration of illicit street opioid selling.

Furst RT.

J Addict Dis. 2014;33(3):177-86. doi: 10.1080/10550887.2014.950030.

PMID:
25115236
18.

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Orman JS, Keating GM.

Drugs. 2009;69(5):577-607. doi: 10.2165/00003495-200969050-00006. Review.

PMID:
19368419
19.

Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.

Lucas GM, Young A, Donnell D, Richardson P, Aramrattana A, Shao Y, Ruan Y, Liu W, Fu L, Ma J, Celentano DD, Metzger D, Jackson JB, Burns D; HPTN 058 study group..

Drug Alcohol Depend. 2014 Sep 1;142:139-45. doi: 10.1016/j.drugalcdep.2014.06.013.

20.

A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Lofwall MR, Walsh SL.

J Addict Med. 2014 Sep-Oct;8(5):315-26. doi: 10.1097/ADM.0000000000000045. Review.

Items per page

Supplemental Content

Support Center